小分子抗血管生成药物在晚期乳腺癌中的研究进展

doi:10.3969/j.issn.1006-5725.2023.22.002

Abstract

Abstract:

By the year of 2020， the number of breast cancer patients has reached the highest worldwide， while the prognosis for advanced breast cancer remains extremely poor. Chemotherapy is currently the main treatment method； however， its strong side effects and the development of drug resistance limit the clinical benefits of the therapy. Neoangiogenesis plays a crucial role in tumor development and metastasis， making anti?angiogenesis therapy a hot point in cancer research. VEGFR， an important vascular endothelial growth factor receptor， promotes blood vessel growth and is overexpressed in multiple tumors including breast cancer. Therefore， inhibiting activity of VEGFR can effectively suppress tumor angiogenesis and normalize tumor blood vessels. Numerous small molecule anti?angiogenesis drugs have been studied clinically for breast cancer treatment. This article aims to explore VEGFR tyrosine kinase inhibitors （VEGFR?TKIs） as an effective treatment option for advanced breast cancer patients， and the efficacy， safety， and potential side effects of these inhibitors. Additionally， it provides new insights into palliative care for advanced breast cancer.

Key words: small molecule anti?angiogenic drugs, advanced breast cancer, research progress, review

CLC Number:

R737.9

Yadan CHE,Lixia. LI. Reaserch progress on small molecule anti⁃angiogenic drugs for advanced breast cancer[J]. The Journal of Practical Medicine, 2023, 39(22): 2866-2871.

References 43

1	SUNG H ， FERLAY J ， SIEGEL RL ， et al . Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin，2021，71（3）：209⁃249.
2	AYOUB N M ， JARADAT S K ， AL⁃SHAMI K M ， et al . Targeting Angiogenesis in Breast Cancer： Current Evidence and Future Perspectives of Novel Anti⁃Angiogenic Approaches［J］. Front Pharmacol， 2022， 13： 838133.
3	HU X ， ZHANG J ， XU B ， et al . Multicenter phase Ⅱ study of apatinib， a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple⁃negative breast cancer［J］. Int J Cancer， 2014， 135（8）： 1961⁃1969.
4	HU X ， CAO J ， HU W ， et al . Multicenter phase Ⅱ study of apatinib in non⁃triple⁃negative metastatic breast cancer［J］. BMC cancer， 2014， 14： 820.
5	LIN Y ， WU Z ， ZHANG J ， et al . Apatinib for metastatic breast cancer in non⁃clinical trial setting： Satisfying efficacy regardless of previous anti⁃angiogenic treatment［J］. Tumour Biol， 2017， 39（6）： 1010428317711033.
6	律慧敏，张梦玮，牛李敏，等 . 甲磺酸阿帕替尼单药治疗多药耐药晚期乳腺癌临床观察［J］. 中华医学杂志， 2018， 98（16）： 1246⁃1249.
7	FAN M ， ZHANG J ， WANG Z ， et al . Phosphorylated VEGFR2 and hypertension： potential biomarkers to indicate VEGF⁃dependency of advanced breast cancer in anti⁃angiogenic therapy［J］. Breast Cancer Res Treat， 2014， 143（1）： 141⁃151.
8	ZHU A ， YUAN P ， WANG J ， et al . Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer： An observational study［J］. Oncol Lett， 2019， 17（6）： 4768⁃4778.
9	ZHU A ， YUAN P ， HU N ， et al . Phase Ⅱ study of apatinib in combination with oral vinorelbine in heavily pretreated HER2⁃negative metastatic breast cancer and clinical implications of monitoring ctDNA［J］. Cancer Biol Med， 2021， 18（3）： 875⁃887.
10	HU N ， ZHU A ， SI Y ， et al . A Phase Ⅱ， Single⁃Arm Study of Apatinib and Oral Etoposide in Heavily Pre⁃Treated Metastatic Breast Cancer［J］. Front Oncol， 2020， 10： 565384.
11	WANG J ， CHEN Y ， CHEN R ， et al . Application of apatinib after multifaceted therapies for metastatic breast cancer［J］. Transl Cancer Res， 2020， 9（8）： 4488⁃4497.
12	LI Y H ， ZHOU Y ， WANG Y W ， et al . Comparison of apatinib and capecitabine （Xeloda） with capecitabine （Xeloda） in advanced triple⁃negative breast cancer as third⁃line therapy： A retrospective study［J］. Medicine （Baltimore）， 2018， 97（36）： e12222.
13	FAN W ， DING J ， ZHONG W . Efficacy and Safety of Third⁃Line Apatinib plus Chemotherapy in Metastatic Triple⁃Negative Breast Cancer Patients： A Multicenter， Retrospective， Cohort Study［J］. Tohoku J Exp Med， 2023， 260（1）：13⁃20.
14	LIU J ， LI Y ， LI Q ， et al . Biomarkers of response to camrelizumab combined with apatinib： an analysis from a phase Ⅱ trial in advanced triple⁃negative breast cancer patients［J］. Breast Cancer Res Treat， 2021， 186（3）： 687⁃697.
15	LIU J ， WANG Y ， TIAN Z ， et al . Multicenter phase Ⅱ trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple⁃negative breast cancer［J］. Nat Commun， 2022， 13（1）： 3011.
16	ZENG T ， SUN C ， LIANG Y ， et al . A Real⁃World Multicentre Retrospective Study of Low⁃Dose Apatinib for Human Epidermal Growth Factor Receptor 2⁃Negative Metastatic Breast Cancer［J］. Cancers （Basel）， 2022， 14（17）： 4084.
17	HE L ， SHEN X ， LIU Y ， et al . The reversal of anti⁃HER2 resistance in advanced HER2⁃positive breast cancer using apatinib： two cases reports and literature review［J］. Transl Cancer Res， 2022， 11（11）： 4206⁃4217.
18	HU N ， SI Y ， YUE J ， et al . Anlotinib has good efficacy and low toxicity： a phase Ⅱ study of anlotinib in pre⁃treated HER⁃2 negative metastatic breast cancer［J］.Cancer Biol Med， 2021， 18（3）： 849⁃859.
19	QIAN Y ， LOU K ， ZHOU H ， et al . Efficacy and safety of anlotinib⁃based treatment in metastatic breast cancer patients［J］. Front Oncol， 2022， 12： 1042451.
20	SHAO Y ， LUO Z ， YU Y ， et al . A real⁃world study of anlotinib as third⁃line or above therapy in patients with her⁃2 negative metastatic breast cancer［J］. Front Oncol， 2022， 12： 939343.
21	吴军，戴明 . 安罗替尼联合吉西他滨+顺铂方案治疗三阴性乳腺癌效果分析［J］. 中华实用诊断与治疗杂志， 2021， 35（8）： 779⁃782.
22	聂琰，谭博，杨旭，等 . 化疗联合安罗替尼对三阴性乳腺癌患者的预后研究［J］. 中国卫生标准管理， 2021， 12（2）： 93⁃95.
23	徐静，陈谦，胡春霞，等 . 盐酸安罗替尼联合白蛋白结合型紫杉醇和顺铂方案治疗转移性三阴性乳腺癌的疗效评价［J］. 中国处方药，2022，12：126⁃129.
24	BASELGA J ， SEGALLA J G M ， ROCHÉ H ， et al . Sorafenib in combination with capecitabine： an oral regimen for patients with HER2⁃negative locally advanced or metastatic breast cancer［J］. J Clin Oncol， 2012， 30（13）： 1484⁃1491.
25	BASELGA J ， ZAMAGNI C ， GÓMEZ P ，et al . RESILIENCE： Phase Ⅲ Randomized， Double⁃Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2⁃Negative Breast Cancer［J］. Clin Breast Cancer， 2017， 17（8）： 585⁃594.e4.
26	DECKER T ， OVERKAMP F ， RÖSEL S ， et al . A randomized phase Ⅱ study of paclitaxel alone versus paclitaxel plus sorafenib in second⁃ and third⁃line treatment of patients with HER2⁃negative metastatic breast cancer （PASO）［J］. BMC Cancer， 2017， 17（1）： 499.
27	GRADISHAR W J ， KAKLAMANI V ， SAHOO T P ， et al . A double⁃blind， randomised， placebo⁃controlled， phase 2b study evaluating sorafenib in combination with paclitaxel as a first⁃line therapy in patients with HER2⁃negative advanced breast cancer［J］. Eur J Cancer， 2013， 49（2）： 312⁃322.
28	MAVRATZAS A ， BAEK S ， GERBER B ， et al . Sorafenib in combination with docetaxel as first⁃line therapy for HER2⁃negative metastatic breast cancer： Final results of the randomized， double⁃blind， placebo⁃controlled phase II MADONNA study［J］. Breast， 2019， 45： 22⁃28.
29	MORIKAWA A ， GRKOVSKI M ， PATIL S ， et al . A phase I trial of sorafenib with whole brain radiotherapy （WBRT） in breast cancer patients with brain metastases and a correlative study of FLT⁃PET brain imaging［J］. Breast Cancer Res Treat， 2021， 188（2）： 415⁃425.
30	ROBERT N J ， SALEH M N ， PAUL D ， et al . Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first⁃line treatment of patients with advanced breast cancer： a phase Ⅲ， randomized， open⁃label trial［J］. Clin Breast Cancer， 2011， 11（2）： 82⁃92.
31	BERGH J ， BONDARENKO I M ， LICHINITSER M R ， et al . First⁃line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone： results of a prospective， randomized phase Ⅲ study［J］. J Clin Oncol， 2012， 30（9）： 921⁃929.
32	CROWN J P ， DIÉRAS V ， STAROSLAWSKA E ， et al . Phase Ⅲtrial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer［J］. J Clin Oncol， 2013， 31（23）： 2870⁃2878.
33	CURIGLIANO G ， PIVOT X ， CORTÉS J ， et al . Randomized phase Ⅱ study of sunitinib versus standard of care for patients with previously treated advanced triple⁃negative breast cancer［J］. Breast， 2013， 22（5）： 650⁃656.
34	SYMONDS L ， JENKINS I ， LINDEN H M ， et al . A Phase ⅡStudy Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G⁃CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer［J］. Clin Breast Cancer， 2022， 22（1）： 32⁃42.
35	张婷，唐志强 . 舒尼替尼联合卡培他滨治疗三阴性乳腺癌对血管生成因子和凋亡因子的影响［J］. 检验医学与临床，2023，20（2）：232⁃236.
36	TAYLOR S K ， CHIA S ， DENT S ， et al . A phase Ⅱ study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma： a trial of the Princess Margaret Hospital phase Ⅱ consortium［J］. Oncologist， 2010， 15（8）： 810⁃818.
37	CRISTOFANILLI M ， JOHNSTON S R D ， MANIKHAS A ， et al . A randomized phase Ⅱ study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer［J］. Breast Cancer Res Treat， 2013， 137（2）： 471⁃482.
38	RUGO H S ， STOPECK A T ， JOY A A ， et al . Randomized， placebo⁃controlled， double⁃blind， phase Ⅱ study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer［J］. J Clin Oncol， 2011， 29（18）： 2459⁃2465.
39	CHEN L ， JIANG Y Z ， WU S Y ， et al . Famitinib with Camrelizumab and Nab⁃Paclitaxel for Advanced Immunomodulatory Triple⁃Negative Breast Cancer （FUTURE⁃C⁃Plus）： An Open⁃Label， Single⁃Arm， Phase Ⅱ Trial［J］. Clin Cancer Res， 2022， 28（13）： 2807⁃2817.
40	HOU W ， DING M ， LI X ， et al . Comparative evaluation of cardiovascular risks among nine FDA⁃approved VEGFR⁃TKIs in patients with solid tumors： a Bayesian network analysis of randomized controlled trials［J］. J Cancer Res Clin Oncol， 2021， 147（8）： 2407⁃2420.
41	LIU Y ， LI Y ， WANG Y ， et al . Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy［J］. J Hematol Oncol， 2022， 15（1）： 89.
42	HUANG M ， LIN Y ， WANG C ， et al . New insights into antiangiogenic therapy resistance in cancer： Mechanisms and therapeutic aspects［J］. Drug Resist Updat， 2022， 64： 100849.
43	CHAN H C S ， SHAN H ， DAHOUN T ， et al . Advancing Drug Discovery via Artificial Intelligence［J］. Trends Pharmacol Sci， 2019， 40（8）： 592⁃604.

[1]	Lulu CHEN,Meng LUO,Kaiqi SU,Jing GAO,Xiaodong. FENG. Research progress of the endoplasmic reticulum⁃mitochondrial interactions in post⁃stroke cognitive impairment [J]. The Journal of Practical Medicine, 2024, 40(7): 1023-1028.
[2]	Sha LI,Chun′ai CUI. Progress in targeted research of forkhead box protein O3a in degenerative disease [J]. The Journal of Practical Medicine, 2024, 40(3): 423-427.
[3]	Shan GAO,Kun JI,Li ZHAO,Yujia XING,Yandong XIE,Xiqiang CAI. Research progress on esophageal squamous intraepithelial neoplasia [J]. The Journal of Practical Medicine, 2024, 40(3): 432-438.
[4]	Ganggang LU,Shenglong LI,Yongqiang ZHAO,Yunpeng JIA,Yonglin LIANG,Yuanbo. ZHAO. Research progress on the correlation between oxidative stress and ferroptosis in diabetic impotence [J]. The Journal of Practical Medicine, 2024, 40(16): 2229-2235.
[5]	Xin DOU,Changhui HE,Xiao MEI,Haidi PAN,Yuanxin MA,Wei. WANG. Research progress on the intervention of traditional Chinese medicine in IBS⁃D based on the "SCFAs⁃intestinal barrier" pathway [J]. The Journal of Practical Medicine, 2024, 40(15): 2177-2182.
[6]	Shan′gao HUANG,Yueling WU,Ying. ZHANG. Aiming for the future： The latest advances in targeted therapy for ovarian cancer [J]. The Journal of Practical Medicine, 2024, 40(14): 1901-1907.
[7]	Haixia YUAN,Xinmin HAN,Tianyi CHEN,Yuchen. SONG. Progress on structural abnormalities in the cerebral cortex in children with attention deficit/hyperactivity disorder [J]. The Journal of Practical Medicine, 2024, 40(10): 1455-1459.
[8]	Yan YANG,Zhen WANG,Defeng. WANG. Clinical research progress of bexagliflozin： A new hypoglycemic drug [J]. The Journal of Practical Medicine, 2023, 39(22): 3015-3020.
[9]	YANG Yan, ZHUO Jian, SHEN Hongxia, HAN Ruimin, WANG Zhen, WANG Defeng.. Research progress of new hypoglycemic drugs in the treatment of type 2 diabetes [J]. The Journal of Practical Medicine, 2023, 39(2): 153-157.
[10]	HE Xiaolong, WANG Wenxin, ZHANG Xin, WANG Fanning, YI Kang, YOU Tao.. Research progress in the application of mechanical circulatory support in fulminant myocarditis [J]. The Journal of Practical Medicine, 2023, 39(12): 1461-1465.
[11]	YANG Yan, HAN Ruimin, LIU Mengru, YAN Jingjing, SUN Li, WANG Defeng. . Progress onfecal microbiota transplantation for diabetes [J]. The Journal of Practical Medicine, 2023, 39(12): 1584-1587.
[12]	LIU Hui, HE Caixian, PENG Jiyong, ZHONG Xi, LIAO Kai, YUAN Yawei, ZHENG Ronghui.. Carotid arterial injuries caused by radiotherapy for nasopharyngeal carcinoma：A review [J]. The Journal of Practical Medicine, 2023, 39(10): 1201-1205.
[13]	LI Yanwei, WANG Bin, MIAO Yulu, LI Xiao⁃ jin, ZHANG Yadong, HAN Juan, ZHUANG Pengwei, ZHANG Yanjun.. Research progress of intestinal barrier dysfunction in sepsis [J]. The Journal of Practical Medicine, 2022, 38(7): 799-803.
[14]	ZHANG Ying, WU Yueling.. Immunotherapy incervical cancer：The advent of precision medicine [J]. The Journal of Practical Medicine, 2022, 38(15): 1856-1859.
[15]	CUI Jiakang, GAO Qingjie, MENG Qingliang.. Effect of CAR ⁃T therapy on rheumatic immune diseases：A systematic literature review [J]. The Journal of Practical Medicine, 2022, 38(13): 1707-1710.

Reaserch progress on small molecule anti⁃angiogenic drugs for advanced breast cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 43

Related Articles 15

Recommended Articles

Metrics

Comments